The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | Evaluating the role of surgery in early non-small cell lung cancer
Paul van Schil, MD, PhD, University Hospital Antwerp, Antwerp, Belgium, discusses current treatment options for patients with early non-small cell lung cancer (NSCLC). Whilst surgery is standard of care in this setting, questions still remain in terms of how minimally invasive surgery should be conducted, and whether surgery should be combined with other modalities. The CALGB 140503 trial (NCT00499330) additionally compares lobar or sublobar surgery for NSCLC. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
